Search results: Sage Journals

Open accessResearch articleFirst published 2022

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness,Resistance Mechanisms,and Prognosis of Different Subsequent Treatments

Naifu Nie, Jianghua Li, Jian Zhang [...]

Clinical Medicine Insights: Oncology

Free accessResearch articleFirst published November, 2013

Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians

Raffaella Palumbo, Federico Sottotetti, Alberto Riccardi [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2025

Real-world evidence for immunotherapy in the first-line or subsequent-line setting in extensive-stage small-cell lung cancer

Ruizi Ren, Ying Wang, Qunhui Wang [...]

Therapeutic Advances in Medical Oncology

Free accessResearch articleFirst published July, 2011

Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer

B. K. Eccles, T. R. Geldart, V. M. Laurence [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published August, 2020

The influence of supervisor bottom-line mentality and employee bottom-line mentality on leader-member exchange and subsequent employee performance

Matthew J Quade, Benjamin D McLarty, Julena M Bonner

Human Relations

Restricted accessResearch articleFirst published March, 2008

Initiation of a Zebrafish Blastula Cell Line on Rainbow Trout Stromal Cells and Subsequent Development Under Feeder-Free Conditions into a Cell Line,ZEB2J

Jerry G. Xing, Lucy E.J. Lee, Lianchun Fan [...]

Zebrafish

Restricted accessResearch articleFirst published April, 2023

The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis

Huilin Xu, Dedong Cao, Fangfang Jie [...]

Tumori Journal

Restricted accessArticle commentaryFirst published September, 2020

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

Jacopo Giuliani, Andrea Bonetti

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published April, 2023

The influence of the tested item on serial dependence in perceptual decisions

Mohsen Rafiei, Andrey Chetverikov, Sabrina Hansmann-Roth [...]

Perception

Free accessResearch articleFirst published April, 2004

Production of Cell Lines Secreting TAT Fusion Proteins

Tibor Barka, Edward S. Gresik, Scott C. Henderson

Journal of Histochemistry & Cytochemistry

Open accessResearch articleFirst published 2022

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness,Resistance Mechanisms,and Prognosis of Different Subsequent Treatments

Naifu Nie, Jianghua Li, Jian Zhang [...]

Clinical Medicine Insights: Oncology

Free accessResearch articleFirst published November, 2013

Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians

Raffaella Palumbo, Federico Sottotetti, Alberto Riccardi [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2025

Real-world evidence for immunotherapy in the first-line or subsequent-line setting in extensive-stage small-cell lung cancer

Ruizi Ren, Ying Wang, Qunhui Wang [...]

Therapeutic Advances in Medical Oncology

Free accessResearch articleFirst published July, 2011

Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer

B. K. Eccles, T. R. Geldart, V. M. Laurence [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published August, 2020

The influence of supervisor bottom-line mentality and employee bottom-line mentality on leader-member exchange and subsequent employee performance

Matthew J Quade, Benjamin D McLarty, Julena M Bonner

Human Relations

Restricted accessResearch articleFirst published March, 2008

Initiation of a Zebrafish Blastula Cell Line on Rainbow Trout Stromal Cells and Subsequent Development Under Feeder-Free Conditions into a Cell Line,ZEB2J

Jerry G. Xing, Lucy E.J. Lee, Lianchun Fan [...]

Zebrafish

Restricted accessResearch articleFirst published April, 2023

The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis

Huilin Xu, Dedong Cao, Fangfang Jie [...]

Tumori Journal

Restricted accessArticle commentaryFirst published September, 2020

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

Jacopo Giuliani, Andrea Bonetti

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published April, 2023

The influence of the tested item on serial dependence in perceptual decisions

Mohsen Rafiei, Andrey Chetverikov, Sabrina Hansmann-Roth [...]

Perception

Free accessResearch articleFirst published April, 2004

Production of Cell Lines Secreting TAT Fusion Proteins

Tibor Barka, Edward S. Gresik, Scott C. Henderson

Journal of Histochemistry & Cytochemistry